TY - JOUR
T1 - Immunohistochemical expression of p53, p21, p16, and cyclin D1 in superficial bladder cancer. A tissue microarray study
AU - Vallmanya Llena, F. R.
AU - Laborda Rodríguez, A.
AU - Lloreta Trull, J.
AU - Cortadella Ángel, R.
AU - Placer Santos, J.
AU - Gelabert Mas, A.
PY - 2006/1/1
Y1 - 2006/1/1
N2 - Introduction and objectivest: To retrospectively assess the relationship between immunohistochemical expression of p53, p21, p 16, and cyclin D1, with recurrence, progression and survival in superficial bladder cancer. Methods: 163 patients undergoing transurethral resection for superficial bladder cancer between February 1995 and March 2004. Tumor samples were included in a tissue microarray support that was serially sectioned for immunohistochemical staining. Grade and stage associations for each marker were evaluated by the Chi-square test. Assessment of the relationship with recurrence, progression, and survival Kaplan-Meier curves and log-rank test were used. Results: There were no statistically significant differences in marker expression depending an tumor grade and stage, with the exception of Cyclin D1, that was significantly different depending on tumor stage (p=0.030). p21 expression was related to tumor recurrence (p=0.035), progression (p=0.008) and survival (p=0.034). p16 expression was also related to recurrence (p=0.048) and survival (p=0.047), but not to tumor progression (p=0.116). p53 and Cyclin D1 were not statistically associated with tumor recurrence, progression or survival. Conclusions: In our experience, only p16 and p21 may be useful in the management of superficial bladder tumors, as they are predictors of recurrence and survival in Ta and T1 patients.
AB - Introduction and objectivest: To retrospectively assess the relationship between immunohistochemical expression of p53, p21, p 16, and cyclin D1, with recurrence, progression and survival in superficial bladder cancer. Methods: 163 patients undergoing transurethral resection for superficial bladder cancer between February 1995 and March 2004. Tumor samples were included in a tissue microarray support that was serially sectioned for immunohistochemical staining. Grade and stage associations for each marker were evaluated by the Chi-square test. Assessment of the relationship with recurrence, progression, and survival Kaplan-Meier curves and log-rank test were used. Results: There were no statistically significant differences in marker expression depending an tumor grade and stage, with the exception of Cyclin D1, that was significantly different depending on tumor stage (p=0.030). p21 expression was related to tumor recurrence (p=0.035), progression (p=0.008) and survival (p=0.034). p16 expression was also related to recurrence (p=0.048) and survival (p=0.047), but not to tumor progression (p=0.116). p53 and Cyclin D1 were not statistically associated with tumor recurrence, progression or survival. Conclusions: In our experience, only p16 and p21 may be useful in the management of superficial bladder tumors, as they are predictors of recurrence and survival in Ta and T1 patients.
KW - Cyclin D1
KW - p16
KW - p21
KW - p53
KW - Tissue microarray
KW - Urothelial carcinoma
U2 - 10.1016/S0210-4806(06)73532-X
DO - 10.1016/S0210-4806(06)73532-X
M3 - Article
SN - 0210-4806
VL - 30
SP - 754
EP - 762
JO - Actas Urologicas Espanolas
JF - Actas Urologicas Espanolas
IS - 8
ER -